Dr. Andreas Rummelt is Chairman and Managing Partner of InterPharmaLink AG, a Management Consulting firm in Basel, Switzerland.
His international career in pharmaceuticals has focused on the areas of technical research & development, manufacturing, and quality as well as on running a generics business as CEO. He has served more than twenty years in executive management positions in the industry.
Dr. Rummelt was formerly Group Head of Quality Assurance and Technical Operations at Novartis, a position he held from 2008 until 2010. He had been a member of the Executive Committee of Novartis from 2006 until his resignation in 2010.
He joined Sandoz Pharma Ltd. in 1985 in Switzerland and held various positions of increasing responsibility in Development. In 1994 he was appointed Head of Worldwide Technical Research and Development, a position he retained following the merger with Ciba-Geigy that created Novartis in 1996. From 1999 to 2004, A. Rummelt served as Global Head of Technical Operations of the Novartis Pharmaceuticals Division in Basel, Switzerland, and from 2004 to 2008, as Global CEO of Sandoz, the Generics Division of Novartis, in Vienna, Austria and Holzkirchen, Germany.
Andreas Rummelt is a member of the Boards of Directors of AstraZeneca, UK (LSE, STO, Nasdaq) and of the privately held companies Alvogen Lux Holdings S.à r.l., L, Cypralis Ltd, UK, Leukocare AG, DE, Polyplus-transfection SA, F and Xellia Pharmaceuticals ApS, DK.
A. Rummelt is pharmacist and earned his Ph.D. in Pharmaceutical Sciences from the University of Erlangen-Nuremberg, Germany, in 1983.
He received his executive training in general management and leadership from the IMD in Lausanne, INSEAD in Fontainebleau, and Harvard Business School in Cambridge, USA.